IPP Bureau
Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India
By IPP Bureau - August 02, 2025
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity
By IPP Bureau - August 02, 2025
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
USPTO issues final rejection of Rampart IC's radiation shield patent claims
By IPP Bureau - August 02, 2025
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Agilent and TIFR Hyderabad join hands to boost metabolism and health research
By IPP Bureau - August 02, 2025
Fermenta receives CEP by EDQM for Vitadee 100 SD
By IPP Bureau - August 01, 2025
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Zydus completes acquisition of 85.6% stake in Amplitude Surgical
By IPP Bureau - August 01, 2025
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
By IPP Bureau - August 01, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025
By IPP Bureau - August 01, 2025
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Bio-Rad names Rajat Mehta as EVP - Global Commercial Operations
By IPP Bureau - August 01, 2025
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
By IPP Bureau - August 01, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche presents new Alzheimer’s research at AAIC 2025
By IPP Bureau - July 31, 2025
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
By IPP Bureau - July 31, 2025
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP
By IPP Bureau - July 31, 2025
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
By IPP Bureau - July 31, 2025
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Bristol Myers Squibb and Bain Capital launch biotech company NewCo
By IPP Bureau - July 31, 2025
NewCo’s pipeline includes five investigational medicines
